The 5 Strategic Decisions That Define IOL Company Trajectory

Why Five Decisions Matter More Than Five Hundred

A founder building an IOL company makes thousands of decisions in the first few years. Most of them are reversible, recoverable, and low-stakes in the long run – the wrong hire can be replaced, the wrong supplier can be switched, the wrong office can be vacated. But a small number of decisions are different. They set the trajectory of the entire company, they are expensive or impossible to reverse, and they shape every decision that follows. Getting these few decisions right is what separates IOL companies that scale into durable businesses from those that struggle for years against constraints they built into themselves at the start.

This is the central insight behind effective IOL company strategy: a handful of decisions disproportionately determine the outcome, and the founder’s most important job is to identify those decisions and get them right. Spending equal attention on every decision treats the trajectory-defining choices the same as the routine ones, which means the high-leverage decisions do not get the deliberation they deserve. The discipline is to recognize which decisions are foundational and to invest the deliberation where it matters most.

This article identifies the five strategic decisions that most define an IOL company’s trajectory, examines the options and trade-offs in each, and provides decision criteria a founder can apply. The five are deliberately chosen for their leverage and their irreversibility – these are the IOL strategic decisions that are hardest to undo and most determinative of where the company ends up. The goal is practical: a framework a founder can use to think through the decisions that will shape the company for a decade.

The five trajectory-defining decisions are:

• Premium versus commodity positioning – where the company chooses to compete
• Build versus license the design capability – how the company obtains its core IP
• Manufacturing footprint – whether to build or contract manufacturing
• Quality infrastructure timing – when to invest in QC capability
• Regulatory and geographic sequencing – which markets to enter, in what order

Decision 1: Premium versus Commodity Positioning

The first and most foundational decision is where to compete. The IOL market divides broadly into commodity monofocal lenses – high volume, low margin, intense price competition – and premium lenses including toric, multifocal, and EDOF designs – lower volume, high margin, differentiated on performance. This single choice cascades into nearly every other decision the company makes.

 

Dimension	Commodity Monofocal	Premium (Toric / Multifocal / EDOF)
Margin profile	Low; competes on price	High; competes on performance
Volume requirement	High volume essential	Lower volume viable
Capital intensity	High (scale-driven)	High (capability-driven)
QC sophistication	Moderate	High (wavefront-level verification)
Regulatory burden	Established pathways	More demanding, especially for novel designs
Competitive moat	Cost and scale	Technology, IP, clinical evidence
Time to profitability	Faster if scale achieved	Longer; depends on differentiation

 

The strategic trade-offs to weigh:

• Commodity positioning competes on cost, which favors players with scale and capital. A new entrant without scale advantages faces structural disadvantage in commodity monofocal.
• Premium positioning competes on differentiation, which favors players with strong design capability and clinical evidence. A new entrant with genuine technical differentiation can compete against larger players.
• Margins in premium IOLs can be several times those in commodity monofocal, but premium markets are smaller and harder to enter.
• The two positions require different organizations – commodity favors operational excellence and cost discipline; premium favors R&D depth and clinical sophistication.

For most new IOL ventures, premium positioning offers the more defensible path, because competing on cost against established commodity players is structurally difficult. The market opportunity in premium EDOF IOLs illustrates the dynamics that make premium positioning attractive for differentiated entrants. The decision should be made deliberately and early, because nearly everything else in the IOL company strategy follows from it.

What getting Decision 1 right looks like:

• The positioning matches the company’s actual capabilities – premium positioning backed by genuine technical depth, or commodity positioning backed by genuine cost advantage.
• The positioning is chosen, not defaulted into. Companies that drift into a position without choosing it often end up stuck between premium and commodity, with neither the cost structure to win on price nor the differentiation to win on performance.
• The whole organization understands the positioning and aligns to it – R&D, manufacturing, regulatory, and commercial all operating from the same strategic premise.

The most dangerous outcome of Decision 1 is the stuck-in-the-middle position: a company that competes in premium categories without genuine differentiation, or in commodity categories without genuine cost advantage. This middle position combines the disadvantages of both – the high cost structure of premium with the thin margins of commodity. A clear IOL company strategy avoids the middle by committing decisively to one position and building the organization that position requires.

Decision 2: Build versus License the Design Capability

The second decision concerns how the company obtains its core intellectual property: the optical designs that define its products. The options span a spectrum from fully internal design development through licensing existing designs to acquiring design capability through partnership or acquisition.

 

Approach	Advantages	Disadvantages
Build internal R&D	Full IP ownership; differentiation; long-term capability	High cost; slow; requires scarce talent
License existing designs	Fast to market; lower upfront cost; proven designs	Ongoing royalties; limited differentiation; dependency
Acquire design capability	Immediate capability and IP; team included	High acquisition cost; integration risk
Hybrid (license + build)	Fast entry while building capability	Requires managing both models simultaneously

 

Key considerations in the build-versus-license choice:

• Internal R&D builds durable competitive advantage but takes years and requires hiring scarce optical design talent. It is the path to genuine differentiation but the slowest and most expensive.
• Licensing accelerates time to market dramatically but limits differentiation and creates ongoing dependency on the licensor. Companies built entirely on licensed designs compete on execution rather than technology.
• Acquisition delivers capability immediately but carries integration risk and high cost. It suits well-capitalized entrants more than bootstrapped ventures.
• Many successful IOL companies use a hybrid path: license to enter the market quickly while building internal R&D capability for the next generation.

The decision interacts directly with the positioning decision. Premium positioning generally requires stronger internal design capability, because differentiation is the basis of premium competition. Commodity positioning can rely more heavily on licensed or established designs, because the competition is on cost rather than design. A founder choosing premium positioning should weight internal R&D capability more heavily; one choosing commodity positioning can lean more on licensing.

Timing matters as much as the choice itself. Building internal R&D capability takes years – recruiting optical designers, building design infrastructure, accumulating the institutional knowledge that produces good designs. A company that decides to build internal capability must start early, because the capability will not be ready when needed if the decision is deferred. A company that licenses to enter quickly buys time to build, but only if it actually invests the bought time in building rather than remaining permanently dependent on licensed designs.

Warning signs that Decision 2 is misaligned:

• Premium positioning with no plan to build differentiating design capability – the company will not be able to sustain premium competition.
• A licensing arrangement treated as permanent rather than as a bridge to internal capability – the company remains dependent and undifferentiated.
• Internal R&D investment that exceeds what the positioning justifies – building capability the strategy does not require wastes scarce capital.

Among the IOL strategic decisions, the design capability choice is the one most often made implicitly rather than explicitly. Founders frequently default to licensing because it is faster and cheaper in the short term, without deciding whether the long-term strategy requires owned capability. Making this decision explicit – deciding deliberately whether the company needs to own its design capability and committing to the path that follows – is the discipline that separates companies with coherent design strategies from those that drift.

Decision 3: Manufacturing Footprint

The third decision is whether to build manufacturing capability in-house or to contract it to specialized manufacturers. IOL manufacturing requires significant capital, specialized equipment, regulatory-compliant facilities, and skilled personnel – making the build-versus-contract decision one of the largest capital commitments the company will face.

The case for in-house manufacturing:

• Full control over quality, process, and intellectual property protection.
• No dependency on contract manufacturer capacity, priorities, or quality.
• Margin capture – the manufacturing margin stays in the company.
• Ability to iterate process and design together, which matters for premium designs.

The case for contract manufacturing:

• Dramatically lower upfront capital requirement.
• Faster time to market – no facility build-out.
• Access to established regulatory-compliant facilities and processes.
• Flexibility to scale up or down without fixed-asset commitment.

The decision is rarely permanent – many companies start with contract manufacturing and build in-house capability as they scale, or maintain a hybrid where core products are made in-house and others are contracted. The economics shift with volume: at low volume, contract manufacturing is usually more efficient, while at high volume, in-house manufacturing captures more margin. The economics of scaling premium IOL production illustrates how the build-versus-contract calculus shifts as volume grows. For most founders, the practical question is not in-house versus contract forever, but which to start with and when to transition.

The transition trigger points to watch:

• Volume reaches the level where in-house manufacturing margin exceeds the cost of building and operating the facility.
• Quality control needs exceed what the contract manufacturer can reliably deliver, particularly for premium designs.
• IP protection concerns make external manufacturing a strategic risk.
• Contract manufacturer capacity or priorities no longer align with the company’s growth.

The manufacturing decision also interacts with the quality decision that follows. Contract manufacturing places quality control partly in the contract manufacturer’s hands, which premium positioning may find unacceptable. A company committed to premium positioning and demonstrable quality may favor in-house manufacturing earlier than volume economics alone would suggest, because controlling quality directly is part of the premium value proposition. The manufacturing footprint decision cannot be made in isolation from the positioning and quality decisions it connects to.

Decision 4: Quality Infrastructure Timing

The fourth decision is when to invest in quality control infrastructure. This decision is frequently underestimated by founders focused on design and market entry, yet the timing of QC investment has outsized effects on regulatory approval, clinical outcomes, and the company’s ability to scale. The core tension is between investing early – when capital is scarce and revenue is distant – and investing late – when quality problems may already have accumulated.

The risks of investing in quality infrastructure too late:

• Quality problems discovered in clinical trials or post-market, when they are most expensive to fix.
• Regulatory submissions delayed or rejected for inadequate quality data.
• Scaling blocked because the QC system cannot handle production volume.
• Reputation damage from field failures that better QC would have caught.

The risks of investing too early:

• Capital consumed before it is needed, straining a cash-constrained startup.
• Infrastructure built for a product or volume that changes before it is used.

For premium IOL companies, the balance tilts toward investing in QC capability earlier rather than later, because premium positioning depends on demonstrable quality and because premium designs require sophisticated verification that cannot be improvised late. Wavefront-based measurement systems such as the IOLA MFD and model-eye MTF systems such as the IOLA 4C provide the measurement capability that premium IOL verification requires, and the timing of acquiring such capability is a strategic decision rather than a procurement detail. These systems support a manufacturer’s compliance efforts with standards such as ISO 11979; they do not themselves confer compliance, which the manufacturer must establish through its own quality system.

The decision criterion: invest in quality infrastructure ahead of the point where its absence would block progress. For premium IOL companies, this generally means establishing wavefront-level measurement capability before clinical studies begin, because the clinical and regulatory work depends on the quality data the infrastructure produces.

Quality infrastructure timing is where IOL company strategy most often reveals whether the founder truly understands premium positioning. A founder who treats quality as a cost to defer until forced has not internalized that quality is the premium value proposition. A founder who invests in quality capability ahead of need, accepting the early capital cost, demonstrates that the premium positioning is real rather than aspirational. The timing of this single decision is one of the clearest signals of whether a company’s premium strategy is genuine, and it shapes the company’s credibility with regulators, surgeons, and investors alike.

Decision 5: Regulatory and Geographic Sequencing

The fifth decision is which markets to enter and in what order. The major regulatory jurisdictions – the United States (FDA), Europe (CE marking under MDR), and others – differ in their requirements, timelines, costs, and market characteristics. The sequence in which a company pursues these markets shapes its capital requirements, time to revenue, and competitive positioning.

 

Sequencing Strategy	Rationale	Trade-off
CE-first (Europe)	Historically faster pathway; earlier revenue	MDR has raised the bar; smaller individual markets
FDA-first (US)	Largest single market; strong reimbursement	Longer, costlier pathway; higher evidence bar
Emerging-markets-first	Lower regulatory barriers; early revenue	Lower margins; limited scale; reputation considerations
Parallel pathways	Maximizes market reach; spreads risk	Highest capital requirement; complex to manage

 

Considerations in the sequencing decision:

• CE-first has historically offered a faster route to revenue, though the EU Medical Device Regulation (MDR) has substantially raised the evidence and quality bar.
• FDA-first targets the largest single market with the strongest reimbursement, but at the cost of a longer, more expensive, evidence-intensive pathway.
• Emerging markets can provide early revenue and clinical experience at lower regulatory barriers, but with lower margins and scale.
• The sequence affects capital needs profoundly – pursuing the most demanding markets first front-loads cost and delays revenue.

Whichever sequence is chosen, the quality and clinical evidence requirements rise over time across all jurisdictions, which reinforces the importance of the quality infrastructure decision. Building quality systems that support compliance with standards such as ISO 11979 for IOL optical properties early in the company’s development positions it for whichever regulatory sequence it pursues, because the underlying quality evidence is required everywhere.

The regulatory sequence has profound capital implications that founders sometimes underestimate. Each market entry consumes capital in regulatory work, clinical evidence generation, and quality system development before any revenue arrives. Pursuing the most demanding markets first – FDA before CE, for example – front-loads this capital consumption and extends the time to first revenue, which can strain a company that has not raised sufficient funding for the chosen sequence. Matching the regulatory sequence to the company’s capital position is as important as matching it to the target market.

Decision criteria for regulatory sequencing:

• Capital available – demanding markets require more capital before revenue; choose a sequence the funding can sustain.
• Target market priority – enter the markets most important to the long-term strategy, in an order that builds toward them.
• Evidence reusability – clinical and quality evidence generated for one market often supports submissions in others; sequence to maximize reuse.
• Competitive timing – in some categories, being early in a specific market carries strategic value worth sequencing around.

How the Five Decisions Interact

The five decisions are not independent. They form an interlocking system, and the most common strategic failures come not from getting a single decision wrong but from choosing decisions that are individually reasonable but collectively incoherent. A coherent IOL company strategy aligns all five decisions around a consistent logic.

Common incoherent combinations to avoid:

• Premium positioning with licensed-only designs and minimal R&D – premium competition requires differentiation that licensing alone cannot provide.
• Commodity positioning with heavy internal R&D investment – commodity competition is on cost, and R&D investment that does not lower cost is misallocated.
• Premium positioning with delayed quality infrastructure – premium claims require demonstrable quality from the start.
• Aggressive multi-market regulatory pursuit with inadequate capital – regulatory work is expensive, and spreading thin across markets without capital strains the company.

The coherence test is straightforward: each decision should reinforce the others around a consistent strategic logic. A premium positioning decision should be supported by strong design capability, sophisticated quality infrastructure invested early, manufacturing that protects quality and IP, and a regulatory sequence matched to the company’s capital. When the five decisions reinforce each other, the company has a coherent strategy. When they pull in different directions, the company fights itself.

This coherence is what makes a set of IOL strategic decisions into an actual strategy rather than a list of independent choices. A strategy is a coherent set of mutually reinforcing decisions, not a collection of individually optimal ones. The founder’s task is not to optimize each decision in isolation but to choose a set that works together – sometimes accepting a less-than-optimal individual decision because it strengthens the coherence of the whole. The companies that build durable advantage are those whose five decisions form a tightly integrated system that competitors cannot easily replicate.

The Five-Decision Framework: A Summary

The five decisions, taken together, form a framework a founder can use to think through the company’s trajectory. The summary below brings them together with the core question each decision answers and the primary criterion for resolving it.

 

Decision	Core Question	Primary Criterion
1. Positioning	Premium or commodity?	Where can the company build a defensible advantage?
2. Design capability	Build, license, or acquire?	Does the positioning require owned differentiation?
3. Manufacturing	In-house or contract?	Volume economics and quality/IP control needs
4. Quality timing	When to invest in QC?	Invest ahead of where its absence would block progress
5. Regulatory sequence	Which markets, in what order?	Match the sequence to available capital and target market

 

To apply the framework:

• Resolve the positioning decision first – it constrains the other four.
• Align design capability and quality timing to the positioning choice.
• Choose manufacturing footprint based on volume economics and the positioning’s quality demands.
• Sequence regulatory entry to match capital and the positioning’s target markets.
• Test the whole set for coherence – ensure the five decisions reinforce rather than contradict each other.

Getting the Five Right

An IOL company’s trajectory is set early, by a small number of decisions that are expensive to reverse and that shape everything downstream. The founder who identifies these five decisions, deliberates them carefully, and aligns them into a coherent strategy gives the company a structural advantage that execution alone cannot replicate. The founder who treats them as routine, or who chooses them incoherently, builds constraints into the company that years of execution may not overcome.

None of the five decisions has a universally correct answer. The right positioning, design strategy, manufacturing footprint, quality timing, and regulatory sequence depend on the company’s capital, capability, market, and ambition. What is universal is the leverage these decisions carry and the importance of resolving them deliberately and coherently. The founder’s highest-value strategic work is getting these five right and ensuring they reinforce one another, because a coherent IOL company strategy built on these five decisions is the foundation everything else rests on.

Get the five right, and the rest is execution. Get them wrong, and execution cannot save you.

Disclaimer: This document is intended for educational use only. It does not represent legal, regulatory, financial, or certification advice, and should not be interpreted as a declaration of compliance or approval by Rotlex or any regulatory authority.